argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
argenx (Euronext & Nasdaq: ARGX), a global immunology company, will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and second quarter business update.
The webcast will be accessible through the Investors section of the argenx website at argenx.com/investors, with a replay available for approximately one year. The company has provided international dial-in numbers and the access code 3810049 for participants, who are advised to dial in 15 minutes before the call.
argenx (Euronext e Nasdaq: ARGX), un'azienda globale nel settore dell'immunologia, terrà una conference call e una trasmissione audio in diretta il giovedì 31 luglio 2025 alle 14:30 CET (8:30 ET) per discutere i risultati finanziari del primo semestre 2025 e l'aggiornamento sulle attività del secondo trimestre.
La diretta sarà accessibile nella sezione Investitori del sito argenx all'indirizzo argenx.com/investors, con una replica disponibile per circa un anno. L'azienda ha fornito numeri internazionali per la chiamata e il codice di accesso 3810049 per i partecipanti, che sono invitati a collegarsi 15 minuti prima dell'inizio della call.
argenx (Euronext y Nasdaq: ARGX), una empresa global de inmunología, llevará a cabo una conferencia telefónica y una transmisión de audio en vivo el jueves 31 de julio de 2025 a las 14:30 CET (8:30 a.m. ET) para analizar los resultados financieros del primer semestre de 2025 y la actualización del negocio del segundo trimestre.
La transmisión estará disponible en la sección de Inversores del sitio web argenx en argenx.com/investors, con una repetición accesible durante aproximadamente un año. La empresa ha proporcionado números internacionales para marcar y el código de acceso 3810049 para los participantes, quienes se recomienda que llamen 15 minutos antes de la conferencia.
argenx (유로넥스트 및 나스닥: ARGX)는 글로벌 면역학 기업으로서 2025년 7월 31일 목요일 오후 2시 30분 CET (미국 동부 시간 오전 8시 30분)에 2025년 상반기 재무 실적 및 2분기 사업 업데이트를 논의하기 위한 컨퍼런스 콜 및 오디오 웹캐스트를 개최합니다.
웹캐스트는 argenx 웹사이트의 투자자 섹션 argenx.com/investors를 통해 접속할 수 있으며, 약 1년간 다시보기 서비스가 제공됩니다. 회사는 국제 전화 접속 번호와 참가자용 접속 코드 3810049를 제공하며, 참가자들은 콜 시작 15분 전에 접속할 것을 권장합니다.
argenx (Euronext et Nasdaq : ARGX), une entreprise mondiale en immunologie, organisera une conférence téléphonique et une diffusion audio en direct le jeudi 31 juillet 2025 à 14h30 CET (8h30 ET) pour discuter des résultats financiers du premier semestre 2025 et de la mise à jour commerciale du deuxième trimestre.
La diffusion sera accessible via la section Investisseurs du site argenx à l'adresse argenx.com/investors, avec un replay disponible pendant environ un an. L'entreprise a fourni des numéros d'accès internationaux ainsi que le code d'accès 3810049 pour les participants, qui sont invités à se connecter 15 minutes avant le début de l'appel.
argenx (Euronext & Nasdaq: ARGX), ein globales Immunologie-Unternehmen, wird am Donnerstag, den 31. Juli 2025 um 14:30 Uhr CET (8:30 Uhr ET) eine Telefonkonferenz und einen Audio-Webcast veranstalten, um die Finanzergebnisse für das erste Halbjahr 2025 sowie ein Update zum Geschäft im zweiten Quartal zu besprechen.
Der Webcast ist über den Investor-Bereich auf der argenx-Website unter argenx.com/investors zugänglich, wobei eine Wiederholung für etwa ein Jahr verfügbar sein wird. Das Unternehmen stellt internationale Einwahlnummern sowie den Zugangscode 3810049 für Teilnehmer bereit, die empfohlen werden, 15 Minuten vor Beginn der Konferenz einzuwählen.
- None.
- None.
July 24, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When will argenx (ARGX) report its half year 2025 financial results?
How can investors access argenx's (ARGX) half year 2025 earnings call?
Will argenx's (ARGX) earnings call webcast be available for replay?
What is the access code for argenx's (ARGX) half year 2025 earnings call?
